CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)Product type:GuidanceProgramme:NICE guidelineLast updated: 28 September 2023Published: 1 April 2020
COVID-19 rapid guideline: managing COVID-19 (NG191)Product type:GuidanceProgramme:NICE guidelineLast updated: 8 May 2024Published: 23 March 2021
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)Product type:GuidanceProgramme:NICE guidelineLast updated: 25 January 2024Published: 18 December 2020
COVID-19 technology appraisal recommendations: surveillance and rapid update process statement consultationStatus:In developmentProgramme:NICE generalExpected publication date: TBC
Cytokine adsorption technologies for treating respiratory failure in people with COVID-19Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over TS ID 11892Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ensitrelvir for treating COVID-19 [ID6231]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC
FebriDx for C-reactive protein and myxovirus resistance protein A testingStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Molnupiravir for treating COVID-19 [ID6340]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 13 March 2024Published: 29 March 2023
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Remdesivir for treating COVID-19 [ID3808]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
RespirasenseStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
RespiraSense (MT736)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Sabizabulin for treating COVID-19 TS ID 11814Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sipavibart for preventing COVID-19 [ID6282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023
Vilobelimab for treating COVID-19 TS ID 11815Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC